LPL Financial’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $327K | Buy |
+4,550
| New | +$259K | ﹤0.01% | 5132 |
|
|
2025
Q4 | – | Sell |
-4,754
| Closed | -$271K | – | 6003 |
|
|
2025
Q3 | $271K | Buy |
+4,754
| New | +$157K | ﹤0.01% | 5134 |
|
|
2025
Q2 | – | Sell |
-4,134
| Closed | -$42.2K | – | 5651 |
|
|
2025
Q1 | $42.2K | Buy |
4,134
+54
| +1% | +$706 | ﹤0.01% | 5167 |
|
|
2024
Q4 | $56.9K | Sell |
4,080
-303
| -7% | -$5.34K | ﹤0.01% | 5089 |
|
|
2024
Q3 | $85.5K | Buy |
4,383
+1,097
| +33% | +$20.9K | ﹤0.01% | 4919 |
|
|
2024
Q2 | $61.1K | Buy |
3,286
+920
| +39% | +$19.4K | ﹤0.01% | 4817 |
|
|
2024
Q1 | $33.2K | Sell |
2,366
-1
| -0% | -$10 | ﹤0.01% | 4800 |
|
|
2023
Q4 | $20.1K | Hold |
2,367
| – | – | ﹤0.01% | 4731 |
|
|
2023
Q3 | $21.1K | Buy |
2,367
+1,673
| +241% | +$16.1K | ﹤0.01% | 4601 |
|
|
2023
Q2 | $5.99K | Sell |
694
-3
| -0.4% | -$32 | ﹤0.01% | 4576 |
|
|
2023
Q1 | $7.35K | Buy |
697
+2
| +0.3% | +$61 | ﹤0.01% | 4467 |
|
|
2022
Q4 | $23.6K | Sell |
695
-703
| -50% | -$34K | ﹤0.01% | 4350 |
|
|
2022
Q3 | $67K | Buy |
1,398
+10
| +0.7% | +$595 | ﹤0.01% | 4186 |
|
|
2022
Q2 | $79K | Sell |
1,388
-743
| -35% | -$46.9K | ﹤0.01% | 4169 |
|
|
2022
Q1 | $172K | Sell |
2,131
-53
| -2% | -$7.84K | ﹤0.01% | 3861 |
|
|
2021
Q4 | $443K | Buy |
2,184
+129
| +6% | +$28K | ﹤0.01% | 3384 |
|
|
2021
Q3 | $554K | Sell |
2,055
-87
| -4% | -$20.9K | ﹤0.01% | 3126 |
|
|
2021
Q2 | $551K | Buy |
2,142
+42
| +2% | +$11.6K | ﹤0.01% | 3076 |
|
|
2021
Q1 | $630K | Buy |
2,100
+33
| +2% | +$10.3K | ﹤0.01% | 2827 |
|
|
2020
Q4 | $527K | Buy |
2,067
+348
| +20% | +$89.9K | ﹤0.01% | 2706 |
|
|
2020
Q3 | $428K | Sell |
1,719
-144
| -8% | -$45.3K | ﹤0.01% | 2598 |
|
|
2020
Q2 | $647K | Buy |
1,863
+195
| +12% | +$60.8K | ﹤0.01% | 2165 |
|
|
2020
Q1 | $447K | Buy |
1,668
+225
| +16% | +$69.6K | ﹤0.01% | 2164 |
|
|
2019
Q4 | $467K | Buy |
1,443
+144
| +11% | +$41.8K | ﹤0.01% | 2435 |
|
|
2019
Q3 | $355K | Sell |
1,299
-283
| -18% | -$104K | ﹤0.01% | 2542 |
|
|
2019
Q2 | $845K | Sell |
1,582
-58
| -4% | -$29.1K | ﹤0.01% | 1852 |
|
|
2019
Q1 | $826K | Buy |
1,640
+373
| +29% | +$221K | ﹤0.01% | 1788 |
|
|
2018
Q4 | $625K | Buy |
1,267
+889
| +235% | +$537K | ﹤0.01% | 1872 |
|
|
2018
Q3 | $346K | Buy |
378
+17
| +5% | +$14.5K | ﹤0.01% | 2551 |
|
|
2018
Q2 | $264K | Buy |
361
+136
| +60% | +$157K | ﹤0.01% | 2767 |
|
|
2018
Q1 | $359K | Buy |
+225
| New | +$290K | ﹤0.01% | 2450 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
LPL Financial's NKTR Position: Q1 2026 in Review
LPL Financial opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 4,550 shares worth $327K. The stake represents ﹤0.01% of the portfolio and ranks #5132 among its holdings. This is a return to the name: LPL Financial previously reported a position in NKTR as recently as Q3 2025.
LPL Financial first reported a position in NKTR in Q1 2018 and has held it in 31 quarters since. The position peaked at $845K in Q2 2019. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- LPL Financial held 4,550 shares of Nektar Therapeutics worth $327K as of Q1 2026.
- Nektar Therapeutics was a new LPL Financial position in Q1 2026.
- Nektar Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5132 holding.
- LPL Financial first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 31 quarters since.
- LPL Financial's Nektar Therapeutics position peaked at $845K in Q2 2019.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.